BioNexus Gene Lab Common Stock Net 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab common stock net from 2019 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab common stock net from 2019 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$91.4B
Cencora (COR)	$47.5B
DiDi Global (DIDIY)	$23.3B
Natera (NTRA)	$21.4B
ICON (ICLR)	$16.1B
Viatris (VTRS)	$15.6B
Avantor (AVTR)	$13.4B
Revvity (RVTY)	$13.4B
CochLear (CHEOY)	$12.8B
BioMerieux (BMXMF)	$12.7B
Solventum (SOLV)	$11.6B
Medpace Holdings (MEDP)	$9.8B
Doximity (DOCS)	$9.6B
Charles River Laboratories (CRL)	$9.5B
HealthEquity (HQY)	$9B
Sonic Healthcare (SKHHY)	$8.8B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Sotera Health (SHC)	$3.9B
Organon (OGN)	$3.8B
BrightSpring Health Services (BTSG)	$3.2B
Surgery Partners (SGRY)	$2.9B
PACS (PACS)	$2.6B
Concentras Parent (CON)	$2.6B
Ardent Health Partners (ARDT)	$2.4B
Premier (PINC)	$2.1B
Alignment Healthcare (ALHC)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GeneDx Holdings (WGS)	$2B
GoodRx Holdings (GDRX)	$1.6B